Salute e Benessere
Non-Insulin Therapies for Diabetes Market to Reach USD 58.6 Billion by 2034, Driven by Innovative Drug Mechanisms and Rising Global Awareness | States TMR
Non-insulin therapies are generally preferred by healthcare personnel in patients suffering from type 2 diabetes, in which body either fails to produce enough insulin or is incapable of using the insulin that it produces. Certain non-insulin agents facilitate increase of insulin release from the pancreatic cells (sulfonylureas), whereas some of them increase glucose uptake peripherally and reduce hepatic glucose output (Biguanides).
There are agents slowing down digestion of starch in the small intestine (alpha glucosidase inhibitors). Certain medications facilitate reduction of post-meal sugar by blocking some enzymes (Incretin mimetics). The last decade has seen a drastic rise in launching and approvals of non-insulin therapies for diabetes. Various drugs under the category of SGL2 inhibitors such as Empagliflozin, Canagliflozin, and Dapagliflozin were launched after 2013.
Type 2 diabetes occurs in adults when body turns out to be resistant to insulin or does not produce insulin sufficient for the body. In other words, type 2 diabetes happens due to improper regulation of body sugar as fuel. As per the World Health Organization, 422 million people worldwide are living with diabetes, with 1.5 million succumbing to it. Need to combat type 2 diabetes through non-insulin therapies is thus driving the non-insulin therapies for diabetes market.
From organizing clinical trials to seeking regulatory approval, the non-insulin therapies for diabetes landscape is experiencing noteworthy developments. Companies are pooling in a substantial amount of resources to fund trials and research and development projects. Some key providers of non-insulin therapies for diabetes include:
, a global registered at Wilmington, Delaware , United States , provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
:
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
+1-518-618-1030
: 866-552-3453
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/non-insulin-therapies-for-diabetes-market-to-reach-usd-58-6-billion-by-2034--driven-by-innovative-drug-mechanisms-and-rising-global-awareness--states-tmr-302212359.html